证券代码：300233 证券简称：金城医药 公告编号：2025-069 山东金城医药集团股份有限公司 关于子公司收到药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 | 产品 | 剂型 | 注册 | 规格 | 包装 药品批准 | 审批结论 | | --- | --- | --- | --- | --- | --- | | 名称 | | 分类 | | 规格 文号 | | | 丁二磺 | | | | | 本品符合药品注册的有关要 | | 酸腺苷 | | 化学药 | | 10 片/ | 求，批准注册，发给药品注册 | | 蛋氨酸 | 片剂 | | 0.5g | 板，1 板 | 证书。质量标准、说明书、标 | | 肠溶片 | | 品 4 类 | | /盒 | 签及生产工艺照所附执行。药 | | | | | | | 品生产企业应当符合药品生产 | | | | | | | 质量管理规范要求方可生产销 | | | | | | | 售。 | | | | | | 国药准字 H20255778 | 根据《中华人民共和国药品管 | | | | | | | 上市许 ...

山东金城医药集团股份有限公司 第六届董事会第十七次会议决议公告 证券代码：300233 证券简称：金城医药 公告编号：2025-070 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东金城医药集团股份有限公司（以下简称"公司"）第六届董事会第十七 次会议通知于 2025 年 10 月 13 日以邮件通知方式发出。本次董事会会议于 2025 年 10 月 23 日在公司会议室以现场和通讯相结合的方式召开。会议应出席董事 9 名，实际出席会议董事 9 名，其中独立董事王新宇、蔡启孝以通讯方式出席本次 会议。独立董事李福利委托独立董事王新宇出席本次会议，非独立董事王辉、张 忠政分别委托非独立董事马钦元、崔希礼出席本次会议。 本次会议由董事长赵叶青主持，公司部分高级管理人员列席了会议。会议的 召开和表决程序符合《中华人民共和国公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 1、审议通过《关于 2025 年第三季度报告的议案》。 经公司全体董事审议，一致认为：公司 2025 年第三季度报告编制和审核的 程序符合相关法律法规，报告内 ...

山东金城医药集团股份有限公司 2025 年第三季度报告 重要内容提示： 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个 别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第三季度财务会计报告是否经过审计 □是 否 证券代码：300233 证券简称：金城医药 公告编号：2025-071 山东金城医药集团股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 1 山东金城医药集团股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末比上 年初至报告期末 | | | --- | --- | --- | --- | --- | | | | 增减 | 年同期增减 | | | 营业收入（元） | 571,784,910.94 | -24.44% ...

Core Viewpoint - Jincheng Pharmaceutical announced that its subsidiary, Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd., has received a drug registration certificate for Morpholine Nitrozole Sodium Injection from the National Medical Products Administration [2] Group 1 - The announcement was made on the evening of October 20 [2] - The drug registration certificate is a significant regulatory milestone for the company [2] - This development may enhance the product portfolio and market presence of Jincheng Pharmaceutical [2]

Group 1 - Yonghe Co., Ltd. reported a net profit of 469 million yuan for the first three quarters, a year-on-year increase of 220.39% [1] - Jinli Permanent Magnet achieved a net profit of 515 million yuan, reflecting a year-on-year growth of 161.81% [1][2] - Sanhe Pharmaceutical Auxiliary's net profit increased by 8.28% year-on-year, reaching 133 million yuan [2] Group 2 - Jiahuan Technology experienced a net profit decline of 26.53%, totaling 55.35 million yuan [3] - Wuchan Huaneng reported a net profit decrease of 15.10%, amounting to 453 million yuan [3] - Chuan Investment Energy's net profit fell by 4.54%, totaling 4.22 billion yuan [4][5] Group 3 - Dayang Bio's net profit grew by 56.12%, reaching 80 million yuan [5] - Weili Medical reported a net profit increase of 14.94%, totaling 192 million yuan [6] - People's Tongtai's net profit decreased by 45.69%, amounting to 112 million yuan [7] Group 4 - Jiuhuan Bio received a medical device registration certificate for its NT-proBNP test kit [8] - Jincheng Pharmaceutical's subsidiary obtained a drug registration certificate for a specific injection [9] - Guangdian Yuntong's subsidiary acquired a money service operator license in Hong Kong [10] Group 5 - Dash Intelligent won a bid for a project worth 96 million yuan related to the Shijiazhuang subway [10] - Alloy Investment's net profit increased by 124.87%, reaching 7.26 million yuan [11] - Kaile Co., Ltd. reported a net profit growth of 159.14%, totaling 21.63 million yuan [12] Group 6 - Chuanjinno's net profit surged by 175.61%, reaching 304 million yuan [14] - Rijiu Optoelectronics reported a net profit increase of 36.54%, totaling 76.91 million yuan [15] - Dazhu CNC's net profit grew by 142.19%, amounting to 492 million yuan [15] Group 7 - Nairui Radar expects a net profit increase of 181% for the first three quarters [17] - Suzhou Tianmai successfully acquired land use rights for a new manufacturing project [19] - Aokai Pharmaceutical announced clinical research data for its innovative drug at a major conference [21][22] Group 8 - Jilin Aodong's subsidiary passed the consistency evaluation for a specific injection [24] - Qinxin Environment announced the resignation of a board member [25] - *ST Baoying is planning a change in control, leading to a stock suspension [26] Group 9 - Jianlang Hardware's director plans to reduce holdings by up to 500,000 shares [27] - Taihe Technology's director intends to reduce holdings by up to 606,000 shares [29] - Zhongyuan Securities announced a cash dividend of 0.008 yuan per share [31] Group 10 - Beijing-Shanghai High-Speed Railway plans to distribute a cash dividend of 0.0385 yuan per share [32] - Zhuhai Guanyu expects a net profit increase of 36.88%-55.54% for the first three quarters [34] - Shenglong Co., Ltd. reported a net loss of 72.95 million yuan for the first three quarters [36] Group 11 - Shuangyuan Technology plans to distribute a cash dividend of 0.125 yuan per share [38] - Shaanxi Guotou A reported a net profit increase of 6.6%, totaling 996 million yuan [40] - Sunshine Nuohua intends to invest 15 million yuan in a biotech company [41] Group 12 - Yangjie Technology's net profit increased by 45.51%, reaching 974 million yuan [42] - Xingwang Yuda reported a net profit growth of 260%, totaling 38.37 million yuan [43] - Tongyou Technology turned a profit with a net profit of 9.29 million yuan [44]

Core Viewpoint - Jincheng Pharmaceutical's subsidiary has received a drug registration certificate for a new injection, indicating a significant development in its product portfolio and potential market expansion [1] Company Summary - Jincheng Pharmaceutical's subsidiary, Jincheng Jinsu, has been granted a registration certificate by the National Medical Products Administration for the injection of Morpholine Nitrosyl Sodium [1] - The newly approved drug is indicated for treating infections in adults (≥18 years) caused by sensitive bacteria, which may enhance the company's therapeutic offerings [1] Industry Summary - The approved drug targets several types of infections, including pelvic inflammatory disease caused by Streptococcus and Bacteroides, as well as appendicitis and mixed infections involving anaerobic and aerobic bacteria [1] - This development reflects ongoing advancements in the pharmaceutical industry, particularly in addressing complex bacterial infections [1]

智通财经APP讯，金城医药(300233.SZ)公告，公司控股子公司广东金城金素制药有限公司(简称"金城金 素")的通知，金城金素收到国家药品监督管理局下发的吗啉硝唑氯化钠注射液药品注册证书。 公告显示，吗啉硝唑为5-硝基咪唑类抗菌药物，本品通过将奥硝唑中不稳定的氯离子改为较为稳定的吗 啉环，使其结构更稳定，且不良反应发生率更低。本品适用于敏感细菌引起的下列成人(≥18岁)感染：1. 由包括消化链球菌、脆弱拟杆菌、韦荣球菌、吉氏拟杆菌等引起的妇科盆腔炎(包括子宫内膜炎、输卵 管炎、输卵管卵巢脓肿、盆腔腹膜炎等);2.由包括拟杆菌属(脆弱拟杆菌、卵形/多型拟杆菌、单形拟杆 菌、普通拟杆菌、拟杆菌属)，梭菌属(产气荚膜梭菌、双酶梭菌、丁酸梭菌及其他梭菌)，梭杆菌属(具 核梭杆菌、可变梭杆菌)，厌氧球菌(消化链球菌、韦荣球菌)等引起化脓性阑尾炎、坏疽性阑尾炎;3.由 于厌氧菌和需氧菌引起的混合性感染盆腔炎、阑尾炎等。 ...

Core Viewpoint - The recent penalty imposed on Jincheng Pharmaceutical's actual controller and chairman, Zhao Yeqing, for manipulating the securities market highlights a lack of compliance awareness among the company's core members and reflects long-standing governance issues within the company, leading to a dual crisis of trust and development for the firm [1][4]. Regulatory Actions - In August of last year, Zhao Yeqing received a notice from the CSRC regarding an investigation into his alleged market manipulation, coinciding with a significant stock reduction by his father, Zhao Hongfu, which raised market suspicions about the motives behind the sell-off [2]. - The penalty announced in September this year significantly reduced the initial proposed fines from March, where Zhao was to forfeit illegal gains of 7.72 million yuan and face a fine of 23.16 million yuan, totaling 30.88 million yuan, to a mere fine of 1.5 million yuan, while maintaining a four-year market ban [2][3]. Company Performance - Jincheng Pharmaceutical has been experiencing a decline in both revenue and profit, with a reported revenue of 1.36 billion yuan in the first half of 2025, down 22.65% year-on-year, and a net profit of 43.38 million yuan, down 66.78% [6]. - The company's core product, the cephalosporin side-chain active ester series, saw a revenue decline of 32.20%, while the formulation products dropped by 29.04%, indicating a significant downturn in its primary revenue sources [6][7]. Financial Metrics - The company's gross profit margin fell to 36.13% in the first half of 2025, a decrease of approximately 4.49 percentage points from the previous year, with all major product lines experiencing a decline in gross margin [7]. - Jincheng Pharmaceutical's R&D investment as a percentage of revenue has been significantly lower than the industry average, with figures of 7.87% and 5.68% in 2023 and 2024, respectively, compared to the industry averages of 12.34% and 12.61% [9]. Strategic Challenges - The company has struggled with a lack of clear strategic direction, failing to effectively transition from its reliance on intermediate products to a more diversified portfolio, which has hindered its ability to adapt to industry trends towards innovative drugs and high-end formulations [11]. - Jincheng Pharmaceutical's international market expansion has also been slow, with overseas revenue declining from 774 million yuan in 2019 to 685 million yuan in 2024, and further down to 708 million yuan in the first half of 2025, indicating a loss of market share [12].

公告显示，吗啉硝唑为5-硝基咪唑类抗菌药物，本品通过将奥硝唑中不稳定的氯离子改为较为稳定的吗 啉环，使其结构更稳定，且不良反应发生率更低。本品适用于敏感细菌引起的下列成人(≥18岁)感染：1. 由包括消化链球菌、脆弱拟杆菌、韦荣球菌、吉氏拟杆菌等引起的妇科盆腔炎(包括子宫内膜炎、输卵 管炎、输卵管卵巢脓肿、盆腔腹膜炎等);2.由包括拟杆菌属(脆弱拟杆菌、卵形/多型拟杆菌、单形拟杆 菌、普通拟杆菌、拟杆菌属)，梭菌属(产气荚膜梭菌、双酶梭菌、丁酸梭菌及其他梭菌)，梭杆菌属(具 核梭杆菌、可变梭杆菌)，厌氧球菌(消化链球菌、韦荣球菌)等引起化脓性阑尾炎、坏疽性阑尾炎;3.由 于厌氧菌和需氧菌引起的混合性感染盆腔炎、阑尾炎等。 金城医药（300233）(300233.SZ)公告，公司控股子公司广东金城金素制药有限公司(简称"金城金素")的 通知，金城金素收到国家药品监督管理局下发的吗啉硝唑氯化钠注射液药品注册证书。 ...

Core Viewpoint - Jincheng Pharmaceutical has received a drug registration certificate from the National Medical Products Administration for its product, Morinazole Sodium Chloride Injection, which is a new antibacterial drug with lower adverse reaction rates and broader applications in treating various infections [1] Group 1: Product Details - Morinazole is a 5-nitroimidazole class antibacterial drug that improves stability by replacing the unstable chloride ion in ornidazole with a more stable morpholine ring [1] - The drug is indicated for adult infections caused by sensitive bacteria, including gynecological pelvic inflammatory diseases and mixed infections of appendicitis [1] Group 2: Indications - The product is suitable for treating pelvic inflammatory diseases caused by bacteria such as Streptococcus, Bacteroides, and Clostridium [1] - It also addresses purulent appendicitis and necrotizing appendicitis caused by anaerobic and aerobic bacteria [1]